Pieris and Servier enter immuno-oncology deal, potential value of $1.8bn
Pieris Pharmaceuticals Inc. and Servier SA have joined forces in an immuno-oncology deal that could turn out up to eight projects and be worth almost $1.8bn.
- Drug Delivery
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.